Background: Preclinical studies demonstrate poly(ADP-ribose) polymerase (PARP) inhibition augments apoptotic response and sensitizes cervical cancer cells to the effects of cisplatin. Given the use of cisplatin and paclitaxel as first-line treatment for persistent or recurrent cervical cancer, we aimed to estimate the maximum tolerated dose (MTD) of the PARP inhibitor veliparib when added to chemotherapy.
Introduction
Cervical cancer remains a leading cause of cancer death worldwide [1] . Though early stage and locally advanced disease are treated with curative intent, $35% of patients will develop recurrent or persistent disease [2] [3] [4] [5] . Based on survival and quality outcome data from randomized controlled trials, the accepted regimen consists of cisplatin and paclitaxel [6] [7] [8] [9] ; however, responses are of short duration, and recurrent and metastatic cervical cancer remains a devastating diagnosis.
In the Gynecologic Oncology Group (GOG), adding bevacizumab to paclitaxel/cisplatin and paclitaxel/topotecan was evaluated. Bevacizumab and chemotherapy resulted in an improvement in median progression-free survival (PFS) and overall survival (OS) when compared with chemotherapy; however, treatment remains palliative with median survival outcomes increasing to 17 months [10] .
Though the use of bevacizumab improved OS, the prognosis for this cancer remains poor, and studies are ongoing to identify more effective therapies. Poly(ADP-ribose) polymerase (PARP) inhibitors are an emerging therapy option with potential utility. PARP-1 and PARP-2, the targets of the PARP inhibitor (PARPi) veliparib, are nuclear enzymes involved in the detection and repair of certain types of DNA-damage. Compared to normal cells, PARP-1 expression is higher in cancer cells, including cervical cancer cells [11] . Additionally, higher expression of PARP-1 in cancer cell lines has been correlated with resistance to chemotherapy and PARPi have been shown to sensitize cancer cells to chemotherapy [12] .
In pre-clinical studies, PARPi have been shown to increase apoptosis in the HeLa cervical cancer cell line and sensitize cancer cells to cisplatin [13] . Deleterious mutations or loss of core components in error-free double-strand break repair [e.g. homologous recombination repair (HRR)] confer PARPi and cisplatin sensitivity. This is best exemplified by BRCA-1/2 deficiency, but also extends to loss of other HRR or Fanconi Anemia (FA) pathway components [14] . The objective of this study was to assess the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of veliparib with paclitaxel and cisplatin chemotherapy in women with persistent or recurrent cervical cancer who had received definitive concurrent chemotherapy and radiation.
Materials and methods

Eligibility criteria
Patients !18 years of age with a histologic diagnosis of recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy and a GOG performance status of 0-2 were eligible. Patients had received prior definitive chemotherapy and radiation therapy and could have received consolidation therapy up to four cycles of paclitaxel and carboplatin. Measurable disease was not required. Patients had to have adequate bone marrow, renal, hepatic, cardiac, and neurologic functions. Exclusion criteria included prior PARPi therapy, inability to swallow pills, previous history of other invasive malignancies, and any uncontrolled inter-current illness that would preclude compliance with study requirements. All patients gave written informed consent before study entry in compliance with institutional, state, and federal regulations.
Study design and safety assessment
The primary objective was to determine the MTD and DLTs of veliparib when combined with cisplatin and paclitaxel in women with persistent or recurrent cervical cancers. Secondary objectives were to examine PFS, OS, and overall response rate (ORR). Veliparib was supplied under a Collaborative Research and Development Agreement between the National Cancer Institute Cancer Therapy Evaluation Program and GOG. Cisplatin and paclitaxel were obtained commercially.
The treatment plan consisted of paclitaxel 175 mg/m 2 intravenously (i.v.) on day 1, cisplatin 50 mg/m 2 i.v. on day 2, and escalating veliparib doses (50, 100, 150, 200, 250, 300, 350, and 400 mg) orally twice daily on days 1-7 every 21 days. Patients continued on therapy until disease progression or adverse events prohibited further therapy or elected to withdraw.
Patients underwent weekly complete blood counts and toxicity assessments. Toxicities were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0). DLTs included the following: dose delay >2 weeks due to failure to recover counts, febrile neutropenia, grade 4 neutropenia lasting >7 days, grade 3 or 4 thrombocytopenia, study related grade 3 or 4 non-hematological toxicity (excluding grade 3 allergic/hypersensitivity reaction), and any drug-related death. Attribution to treatment or other causes was assigned to each adverse event by clinical investigators. No prophylactic growth factors were permitted. Subsequent cycles of combination therapy were not given until ANC !1500/ ll, the platelet count was >100 000/ll, and all non-hematologic toxicity had recovered to grade 1 or less. Patients delayed for >2 weeks were dose reduced per protocol in either chemotherapy or veliparib depending on the adverse event and no dose re-escalation was permitted. Patients, who had a delay of ! 3 weeks or !2 dose reductions were removed from study.
Radiographic imaging (CT scan or MRI) was obtained within 28 days of initial treatment and then every other cycle for the assessment of clinical response per RECIST 1.1 guidelines [16] . Patients who received at least 1 cycle of therapy and had their disease re-evaluated were considered evaluable for response. Patients with clinical deterioration requiring discontinuation of treatment without objective evidence of disease progression at the time were reported as symptomatic deterioration. The best overall response was the best response recorded from the start of the treatment until disease progression/recurrence. Responses of complete (CR) or partial (PR) required confirmation at !4 weeks from initial documentation.
FANCD2 foci staining
The FA triple staining immunofluorescence method using formalin-fixed paraffin-embedded (FFPE) tissues has been previously described [15] . Tissue samples were available from 26 patients. Nineteen patients had one sample tested including 15 from the primary diagnosis (prior to treatment) and 4 in the recurrent setting. Seven patients had testing on tissue from the primary diagnosis and at recurrence. FFPE FANCD2 foci negative cells (PD220 or PD20) and foci positive cells (MCF-7 or FA corrected PD220 or FA corrected PD20) were used as controls on the sample slide during the procedure. The slides were analyzed under a Nikon E-400 fluorescence microscope. The FANCD2 foci were analyzed under a 100x oil objectives.
Statistical design
This study utilized a standard 3 þ 3 design to identify the MTD [17] . Dose escalation for each cohort of three patients continued until a DLT was observed during the first cycle of therapy. If one patient out of three experienced a DLT, an additional three patients were enrolled at that dose level (DL). The MTD was to be estimated by the highest DL at which < 2 patients (amongst 6) experienced a DLT. Clopper-Pearson confidence intervals (CIs) are presented for binary parameters, and Fisher's exact test was used to RRs by FANCD2 foci status. OS was defined as time from date of study entry to death or the date of last contact. PFS was defined as the period from study entry until disease progression, death, or the last date of contact. The Kaplan-Meier method was used to present PFS and OS figures, and log-rank tests were used to compare PFS and OS by FANCD2 foci status.
Results
Patient demographics
Thirty-seven women enrolled between May 2011 and January 2014, three patients were not treated due to voluntarily withdrawal prior to receiving therapy ( Table 1) . The majority of patients were white (91%) and had a performance status of 0-1. Twenty-nine patients (85%) had measurable disease. In addition to primary chemoradiation, two women (treated on DLs 7 and 8) received consolidation chemotherapy prior to enrolling on trial.
Toxicity
Adverse events regardless of attribution to study treatment are listed in Table 2 . At DL 2 (veliparib 100 mg), one patient had grade 2 dyspnea with known mediastinal and hilar lymphadenopathy on CT scan at enrollment. On cycle 1 day 6 of taking the veliparib, the patient developed grade 4 dyspnea that was possibly related to study drug and died 6 days later due to rapid clinical progression based on review of her medical records and repeat CT imaging. This DLT caused expansion of DL 2 without any additional DLTs. At DL 4 (veliparib 200 mg), 1 patient experienced a dose delay >2 weeks due to grade 3 neutropenia and leukopenia. This DL completed with six patients and no further DLTs. In the highest DL of veliparib 400 mg, one patient had febrile neutropenia, and the remaining five patients had no DLTs. However, one patient with a vesicovaginal fistula on cycle 8 day 1 after a dose reduction presented with cardiogenic shock due to neutropenic sepsis and died 6 days after her treatment. Given the observed tolerability at the highest planned dose of veliparib 400 mg twice daily for 7 days with concurrent chemotherapy, this dose is the recommended dose.
Overall, this combination of veliparib, paclitaxel, and cisplatin was well tolerated with the median number of courses being 4 overall and for DLs 1-8 were 4, 8, 6, 4, 4, 8, 7, and 4, respectively. Twelve patients (35%) received !6 cycles on protocol. Six patients had a hypersensitivity reaction to cisplatin at median cycle 6 (range, cycles 3-8) and were withdrawn from study since there was no desensitization protocol defined for the study. The best responses of the hypersensitivity patients with measurable disease are as follows: one complete response and five stable disease. Three patients withdrew from DL 6, 7, and 8 due to grade 2 fatigue, nausea, or neuropathy. 
Efficacy
Twenty-nine patients entered the trial with measurable disease and are evaluable for ORR (Table 3) . Across all 8 DLs, the ORR (complete and partial) was 34% (10/29) (95% CI ¼ 20%-53%). For the cohort with veliparib at 400 mg with concurrent chemotherapy, the RR was 60% (3/5) (95% CI ¼ 23%-88%). Median PFS was 6.2 months (95% CI ¼ 2.9-10.1), and median OS was 14.5 months (95% CI¼ 8.2-19.4) for the entire cohort ( Figure 1A) .
translational study results. A total of 26 patient FFPE tumors were studied for FANCD2 foci. Tumors with positive FANCD2 foci are expected to have more effective and efficient repair of DNA lesions relative to tumors staining negative for FANCD2 foci; hence the latter may be expected to be more responsive to cisplatin and PARPi. In total, 5 tumors (19%) were negative, 3 (12%) were heterogeneous (partial negative), and 18 (69%) were positive ( Figure 1B) . The FANCD2 foci negative or partial negative rate in this cohort of patients was 31%.
Among the 26 patients with known FANCD2 foci status, 22 patients had measurable disease. ORR were 0% (0/3), 33% (1/3), and 44% (7/16) in patients negative, heterogeneous, and positive for the FANCD2 foci (p ¼ 0.529). The PFS and OS by FANCD2 foci status are not shown due to lack of statistical significance.
Discussion
Cervical cancer remains the fourth most common cancer worldwide, and third leading cause of cancer death among women in under developed countries [1] . Hence, cervical cancer remains a global issue.
Chemotherapy remains the main treatment but without durable responses or cure. G3  G4  G3  G4  G3  G4  G3  G4  G3  G4  G3  G4  G3  G4  G3  G4   a   Blood/lymphatics  1  0  2  0  1  0  0  0  0  0  2  0  2  0  3  0  Anemia  1  0  2  0  1  0  0  0  0  0  2  0  2  0  2  0  Febrile A phase III study evaluated the role of cisplatin versus cisplatin and paclitaxel in recurrent cervical cancer, and although the majority of patients received radiation, only a minority (<30%) received chemoradiation for upfront therapy [6] . In the combination arm the median PFS was 4.8 months compared with 2.8 months in the cisplatin arm (p < 0.001), but there was no difference in median OS. Topotecan plus cisplatin versus cisplatin was studied in the same population (57% had prior Total  29  3  5  3  5  3  3  2  5 Best overall response Complete response 2 (7%) chemoradiation), and the combination had both statistically significantly superior PFS (4.6 vs. 2.9 months) and OS (9.4 vs. 6.5 months). However, in patients stratified by radiation 6 chemotherapy, the hazards ratios for PFS were 0.87 and 0.50, respectively; hence suggesting a less beneficial effect in prior chemoradiation patients [17] . A phase III trial of paclitaxel, topotecan, vinorelbine, or gemcitabine with cisplatin had 70%-80% of patients treated with chemoradiation and was closed at the interim analysis for futility [8] . In the clinical trial of chemotherapy 6 bevacizumab, $70% of patients had previous chemoradiation and the median PFS was 8.2 months in bevacizumab arm versus 5.9 months with chemotherapy alone [10] . In the current trial despite all patients having had chemoradiation and over 40% of patients having an adverse histology of adenocarcinoma which is substantially higher than the above trials, the PFS was 6.2 months indicating potential activity of veliparib in this patient population. These results contrast with the phase I/II NRG trial evaluating veliparib and topotecan in a recurrent cervical cancer patient population that had at least one chemotherapy regimen prior to enrollment which found only a 7% clinical benefit rate and did not proceed to phase II [12] . Importantly in this trial, veliparib 10 mg on days 1-5 was likely a sub therapeutic dose and schedule may not have been ideal [18] . In our trial, veliparib dose was able to be escalated to 400 mg. Across all DLs of veliparib with paclitaxel and cisplatin the ORR (CR and PR) was 34% (95% CI ¼ 20%-53%), and at the 400 mg dose 60% (3/5) with measurable disease had a response (95% CI ¼ 23%-88%). The MTD was not achieved since the protocol dose escalation stopped at 400 mg, but this dose of veliparib is higher than the dose achieved in breast and small cell lung cancer clinical trials utilizing a cisplatin doublet regimen [19, 20] .
Veliparib, paclitaxel, and cisplatin were tolerated with manageable side effects. Treatment-related grade 3 anemia (34%) and grade 3/4 neutropenia (65%) were encountered most frequently and were managed with a treatment delay, with the majority not requiring a dose reduction. Hypersensitivity reactions to cisplatin resulting in cessation of protocol therapy occurred in 17.5% of patients, likely attributed to their prior cisplatin exposure during chemoradiation. In future clinical trials, desensitization protocols should be incorporated to avoid patients from missing out on potential clinical benefit from cisplatin in combination with other agents [21] .
The FA pathway is a major mechanism of HRR DNA repair in response to genotoxic insults. Cancer cells with FA deficiency are hypersensitive to DNA damaging agents, such as cisplatin. FANCD2 activation is critical for chemotherapy resistance and is required for the FANCD2 protein to form repairing foci in DNA [22, 23] . Therefore, it would be anticipated that higher RRs would be seen in FANCD2 foci negative patients, but, there were no responses (n ¼ 3). Though not statistically significant, patients with measurable disease and negative foci were alive at the time of the OS analysis. However, with the limitations posed by the small sample size, further studies are needed to demonstrate the true implication of HRR loss and treatment responses.
Though a small sample size, this phase I study demonstrated a promising ORR in a challenging patient population with acceptable toxicities. The therapeutic regimen of veliparib, paclitaxel, and cisplatin warrants further investigation.
